Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Margareth Mwakilasa, an assistant research fellow at Muhimbili University of Health and Allied Sciences in Tanzania and a PhD student in Global Health at University College Dublin, presented her ...

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

A University of New Mexico researcher and assistant professor is breaking barriers in the health community for fellow Native Americans. Hailing from the Diné Nation, Crystal Lee has been researching ...

You also need to undergo HIV testing before taking this medication. This article examines the effectiveness of Descovy for PrEP and how long it may take for the drug to start working. For more ...

PrEP is medicine taken by HIV-negative people to avoid contracting the virus. “The increasing availability of stimulant drugs ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Data from the Centers for Disease Control and Prevention released Tuesday shows meaningful declines in STI rates between 2022 ...

Recent health data reveals an alarming rise in HIV transmission rate between older men and young women, presenting a complex ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

A new proven protocol in which doxycycline is used to prevent sexually transmitted infections, called doxyPEP, has been an ...